查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961334

醫藥4.0市場－全球產業規模、佔有率、趨勢、機會、預測：依設計、技術、最終用戶、地區和競爭格局分類，2021-2031年

Pharma 4.0 Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Design, By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球醫藥 4.0 市場預計將從 2025 年的 107.9 億美元成長到 2031 年的 173.2 億美元，複合年成長率為 8.21%。

醫藥4.0指的是醫藥價值鏈的數位轉型，它利用先進的分析技術、雲端運算和網實整合系統，打造智慧化的自主生產環境。這一市場成長的主要驅動力是迫切需要提高營運效率，以及監管部門對整個生產過程中資料完整性的嚴格要求。此外，對能夠高效處理個人化醫療和小批量生產且成本控制合理的、高度適應性強的生產能力的需求日益成長，也是推動該行業發展的重要因素。

市場概覽
預測期 2027-2031
市場規模：2025年 107.9億美元
市場規模：2031年 173.2億美元
複合年成長率：2026-2031年 8.21%
成長最快的細分市場 基於雲端的
最大的市場 北美洲

然而，這些先進技術的廣泛應用面臨著許多挑戰，其中之一便是如何將現代數位工具與根深蒂固的傳統基礎設施融合。老舊設施的升級改造需要大量的資金投入和複雜的技術調整，這往往會延緩到完全互聯系統的過渡。包裝和精加工技術協會 (PMMI) 在 2024 年的報告中強調了現代化的緊迫性，報告指出，76% 的製藥公司認為柔軟性和快速切換是至關重要的營運改善措施。這項數據表明，企業正面臨巨大的壓力，需要升級其現有產能，以跟上不斷發展的行業標準。

市場促進因素

人工智慧 (AI) 的引入正在深刻改變全球醫藥 4.0 市場，推動藥物發現和開發流程的轉型。這縮短了研發週期，最佳化了實驗工作流程。企業擴大利用生成式人工智慧來識別候選藥物並預測製劑穩定性，從而有效降低了傳統研發中常見的高失敗率。這項技術進步提高了研究效率，使企業能夠迅速將精力集中在有前景的療法上。這些工具在實驗室環境中的快速普及顯而易見。 Pistoia Alliance 於 2024 年 9 月發布的《全球實驗室未來調查》顯示，68% 的生命科學專業人士正在積極使用人工智慧和機器學習，與前一年相比，使用率顯著提高。

同時，IT和OT系統的整合正在推動智慧製造業向更靈活互聯的生產環境轉型。透過將現場營運技術與企業資料系統連接起來，製造商能夠獲得預測性維護和自適應批量生產所需的即時可見性。這種數位轉型對於滿足日益成長的合規性和營運效率需求至關重要。根據羅克韋爾自動化於2024年7月發布的第九份年度《智慧製造：生命科學》報告，96%的生命科學製造商正在使用或評估智慧製造技術。此外，CPHI Online在2024年發布的報告顯示，62%的行業受訪者正在投資減少廢棄物的舉措，這表明數位化成熟度如何促進更廣泛的永續性目標的實現。

市場挑戰

全球製藥4.0市場發展面臨的主要障礙之一是難以將現代數位工具與根深蒂固的傳統基礎設施整合。許多製藥企業仍在使用運作數十年的設備，這些設備基於專有系統，並非為互聯互通而設計。將這些類比設備與現代雲端平台連接起來需要複雜的技術改造和大量的資金投入。前期投資龐大，加上可能中斷檢驗生產線的風險，使得製造商對整個系統的現代化改造猶豫不決。

這種技術不相容性直接限制了市場成長，助長了保守的投資環境。由於整合不相容系統會帶來財務和營運風險，企業常常推遲必要的數位升級，減緩了自主製造技術的應用。這種猶豫不決其實拖慢了產業的發展步伐。例如，包裝和表面處理技術協會 (PMMI) 預測，到 2025 年，美國包裝器材市場的成長率將僅為 2.2%，這一數字反映出，由於該行業難以克服這些棘手的整合障礙，其擴張速度正在放緩。

市場趨勢

智慧互聯實驗室的演進正在迅速改變全球醫藥4.0市場中的品管和臨床前研究領域。這一轉變正從碎片化的數位化轉向全面、人工智慧驅動的生態系統。其顯著特徵是生成式人工智慧的廣泛應用，以自動化傳統上需要人工完成且容易出錯的任務，例如複雜的數據分析、實驗設計和文件記錄。借助這些先進工具，研究團隊可以將海量歷史數據與即時實驗結果整合，從而顯著縮短假設驅動的檢驗時間。皮斯托亞聯盟2024年12月的數據也印證了這個高度互聯環境的趨勢。該聯盟的人工智慧與版權法調查顯示，83%的生命科學專業人士正在研究中使用生成式人工智慧，凸顯了這些技術在實驗室工作流程中的快速整合。

同時，整個產業正經歷著向無紙化和雲端製造的明顯轉變，旨在提升員工潛能並消除人工記錄帶來的延誤。製造商正逐步用雲端原生平台取代孤立的資料孤島和紙本日誌，這些平台提供即時協作和通用存取。這種轉變不僅僅是文件數位化，更著重於利用自動化來輔助操作人員、減輕認知負荷並確保更高的合規性。這一策略轉變也體現在投資趨勢中。根據羅克韋爾自動化公司於2025年6月發布的第十份年度智慧製造報告：生命科學，48%的生命科學製造商正在採用人工智慧和自動化技術來支援其員工，這表明他們正從勞動密集型方法轉向高效的雲端營運。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球醫藥4.0市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 設計上（功能性、數位化成熟度、資料完整性）
    • 按技術分類（巨量資料分析、雲端運算、網實整合系統、其他）
    • 依最終使用者（醫院/診所、門診手術中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美醫藥4.0市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲醫藥4.0市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區醫藥4.0市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東及非洲醫藥4.0市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美醫藥4.0市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球醫藥4.0市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Medtronic Plc
  • Pfizer Inc.
  • Koninklijke Philips NV
  • Abbott Laboratories Inc
  • GlaxoSmithKline plc
  • Boston Scientific Inc.
  • GE Healthcare
  • Johnson & Johnson
  • Lonza Group Ltd.
  • Glatt GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23503

The Global Pharma 4.0 Market is projected to expand from USD 10.79 Billion in 2025 to USD 17.32 Billion by 2031, reflecting a CAGR of 8.21%. Pharma 4.0 signifies the digital evolution of the pharmaceutical value chain, utilizing advanced analytics, cloud computing, and cyber-physical systems to establish smart, autonomous manufacturing settings. This market growth is primarily underpinned by the urgent need for improved operational efficiency and strict regulatory requirements for complete data integrity across production processes. Additionally, the sector is propelled by an increasing demand for adaptable manufacturing capacities capable of handling personalized medicine and reduced batch sizes efficiently without excessive costs.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 10.79 Billion
Market Size 2031USD 17.32 Billion
CAGR 2026-20318.21%
Fastest Growing SegmentCloud Based
Largest MarketNorth America

However, the broad adoption of these advanced technologies encounters a major hurdle in merging modern digital tools with deep-seated legacy infrastructure. Updating aging facilities demands significant capital expenditure and intricate technical alignment, often slowing the shift toward fully interconnected systems. Highlighting the immediate need for modernization, PMMI, The Association for Packaging and Processing Technologies, reported in 2024 that 76% of pharmaceutical manufacturers cited flexibility and quicker changeover as essential operational improvements. This statistic underscores the intense pressure on companies to upgrade their current production capabilities to meet evolving industry standards.

Market Driver

The Global Pharma 4.0 Market is being radically transformed by the incorporation of Artificial Intelligence into drug discovery and development, which speeds up timelines and refines experimental workflows. Companies are increasingly utilizing generative AI to pinpoint new drug candidates and forecast formulation stability, effectively lowering the high failure rates common in conventional R&D. This technological advancement boosts research productivity and enables organizations to quickly shift focus to promising therapeutics. The swift adoption of these tools is clear in laboratory settings; the Pistoia Alliance's 'Lab of the Future 2024 Global Survey' from September 2024 revealed that 68% of life sciences professionals are actively employing AI and machine learning, representing a notable rise in usage from the prior year.

Concurrently, the merging of IT and OT systems for smart manufacturing is propelling the industry toward more flexible and connected production environments. By aligning shop-floor operational technology with enterprise information systems, manufacturers gain the real-time visibility needed for predictive maintenance and adaptable batch production. This digital transition is essential for satisfying the growing demand for regulatory compliance and operational efficiency. As per Rockwell Automation's '9th Annual State of Smart Manufacturing Report: Life Sciences Edition' released in July 2024, 96% of life sciences manufacturers are either using or assessing smart manufacturing technologies. Furthermore, CPHI Online noted in 2024 that 62% of industry respondents are investing in waste reduction initiatives, illustrating how digital maturity facilitates broader sustainability goals.

Market Challenge

A major obstacle to the progress of the Global Pharma 4.0 Market is the difficulty of integrating modern digital tools with deep-rooted legacy infrastructure. Many pharmaceutical manufacturing sites rely on equipment that has served for decades, running on proprietary systems never intended for connectivity. Adapting these analog machines to interface with modern cloud-based platforms requires intricate technical synchronization and significant capital investment. The need for large upfront spending, coupled with the danger of interrupting validated production lines, generates considerable hesitation among manufacturers regarding a full system overhaul.

This technical incompatibility directly limits market growth by encouraging a conservative investment climate. Organizations frequently postpone essential digital upgrades because of the financial and operational risks linked to aligning incompatible systems, thereby retarding the widespread uptake of autonomous manufacturing technologies. Such hesitation effectively slows the industry's development trajectory. For example, PMMI, The Association for Packaging and Processing Technologies, projects a 2.2% growth rate for the U.S. packaging machinery market in 2025, a figure that reflects a subdued pace of expansion as the sector works through these difficult integration hurdles.

Market Trends

The evolution of Smart and Connected Laboratories is swiftly altering the quality control and pre-clinical sectors of the Global Pharma 4.0 Market, transitioning from piecemeal digitization to comprehensive, AI-powered ecosystems. This movement is defined by the robust uptake of generative artificial intelligence to automate intricate data analysis, experimental planning, and documentation-tasks formerly performed manually and susceptible to error. Using these sophisticated tools enables research teams to combine immense volumes of historical data with live experimental findings, greatly reducing the time between hypothesis and validation. Data from the Pistoia Alliance in December 2024 confirms this trend toward hyper-connected environments; their survey on AI and copyright legislation found that 83% of life science professionals now utilize generative AI in their research, highlighting the rapid integration of these technologies into lab workflows.

Concurrently, the industry is undergoing a definitive shift toward Paperless and Cloud-Based Manufacturing, motivated by the desire to enhance workforce potential and remove the delays associated with manual record-keeping. Manufacturers are progressively substituting disconnected data silos and analog logbooks with cloud-native platforms that provide real-time collaboration and universal access. This shift goes beyond simple document digitization; it focuses on utilizing automation to assist human operators, thereby easing cognitive loads and ensuring superior compliance. This strategic pivot is reflected in investment trends: according to Rockwell Automation's '10th Annual State of Smart Manufacturing Report: Life Sciences Edition' from June 2025, 48% of life sciences manufacturers are adopting AI and automation to aid their workforce, signaling a move away from labor-heavy methods toward efficient, cloud-enabled operations.

Key Market Players

  • Medtronic Plc
  • Pfizer Inc.
  • Koninklijke Philips N.V
  • Abbott Laboratories Inc
  • GlaxoSmithKline plc
  • Boston Scientific Inc.
  • GE Healthcare
  • Johnson & Johnson
  • Lonza Group Ltd.
  • Glatt GmbH

Report Scope

In this report, the Global Pharma 4.0 Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharma 4.0 Market, By Design

  • Capabilities
  • Digital Maturity
  • Data Integrity

Pharma 4.0 Market, By Technology

  • Big Data Analytics
  • Cloud Computing
  • Cyber-physical Systems
  • Other

Pharma 4.0 Market, By End User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Pharma 4.0 Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharma 4.0 Market.

Available Customizations:

Global Pharma 4.0 Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharma 4.0 Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Design (Capabilities, Digital Maturity, Data Integrity)
    • 5.2.2. By Technology (Big Data Analytics, Cloud Computing, Cyber-physical Systems, Other)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pharma 4.0 Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Design
    • 6.2.2. By Technology
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharma 4.0 Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Design
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Pharma 4.0 Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Design
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Pharma 4.0 Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Design
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End User

7. Europe Pharma 4.0 Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Design
    • 7.2.2. By Technology
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharma 4.0 Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Design
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End User
    • 7.3.2. France Pharma 4.0 Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Design
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Pharma 4.0 Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Design
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Pharma 4.0 Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Design
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Pharma 4.0 Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Design
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End User

8. Asia Pacific Pharma 4.0 Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Design
    • 8.2.2. By Technology
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharma 4.0 Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Design
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End User
    • 8.3.2. India Pharma 4.0 Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Design
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Pharma 4.0 Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Design
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Pharma 4.0 Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Design
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Pharma 4.0 Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Design
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By End User

9. Middle East & Africa Pharma 4.0 Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Design
    • 9.2.2. By Technology
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharma 4.0 Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Design
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Pharma 4.0 Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Design
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Pharma 4.0 Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Design
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End User

10. South America Pharma 4.0 Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Design
    • 10.2.2. By Technology
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharma 4.0 Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Design
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Pharma 4.0 Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Design
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Pharma 4.0 Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Design
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharma 4.0 Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Medtronic Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Koninklijke Philips N.V
  • 15.4. Abbott Laboratories Inc
  • 15.5. GlaxoSmithKline plc
  • 15.6. Boston Scientific Inc.
  • 15.7. GE Healthcare
  • 15.8. Johnson & Johnson
  • 15.9. Lonza Group Ltd.
  • 15.10. Glatt GmbH

16. Strategic Recommendations

17. About Us & Disclaimer